FUREN Group PharmaceuticalLtd Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
FUREN Group PharmaceuticalLtd has a total shareholder equity of CN¥-2.2B and total debt of CN¥3.2B, which brings its debt-to-equity ratio to -144.8%. Its total assets and total liabilities are CN¥6.2B and CN¥8.4B respectively.
Anahtar bilgiler
-144.8%
Borç/özkaynak oranı
CN¥3.21b
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥173.80m |
| Eşitlik | -CN¥2.22b |
| Toplam yükümlülükler | CN¥8.39b |
| Toplam varlıklar | CN¥6.18b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 600781 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Uzun Vadeli Yükümlülükler: 600781 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 600781 has negative shareholder equity, which is a more serious situation than a high debt level.
Borcun Azaltılması: 600781's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: Whilst unprofitable 600781 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Tahmini Nakit Akışı: 600781 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 6.6% per year.